155 related articles for article (PubMed ID: 36081178)
21. Murine gammaherpesvirus 68 reactivation from B cells requires IRF4 but not XBP-1.
Matar CG; Rangaswamy US; Wakeman BS; Iwakoshi N; Speck SH
J Virol; 2014 Oct; 88(19):11600-10. PubMed ID: 25078688
[TBL] [Abstract][Full Text] [Related]
22. IRF4: Immunity. Malignancy! Therapy?
Shaffer AL; Emre NC; Romesser PB; Staudt LM
Clin Cancer Res; 2009 May; 15(9):2954-61. PubMed ID: 19383829
[TBL] [Abstract][Full Text] [Related]
23. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Kawano Y; Fujiwara S; Wada N; Izaki M; Yuki H; Okuno Y; Iyama K; Yamasaki H; Sakai A; Mitsuya H; Hata H
Int J Oncol; 2012 Sep; 41(3):876-84. PubMed ID: 22766978
[TBL] [Abstract][Full Text] [Related]
24. A neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency.
Thouenon R; Chentout L; Moreno-Corona N; Poggi L; Lombardi EP; Hoareau B; Schmitt Y; Lagresle-Peyrou C; Bustamante J; André I; Cavazzana M; Durandy A; Casanova JL; Galicier L; Fadlallah J; Fischer A; Kracker S
J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36917008
[TBL] [Abstract][Full Text] [Related]
25. A novel missense mutation of the XBP1 gene in diffuse large B-cell lymphoma.
Tate G; Kishimoto K; Hirayama Y; Suzuki T; Mitsuya T
Cancer Genet Cytogenet; 2009 Apr; 190(2):131-3. PubMed ID: 19380033
[TBL] [Abstract][Full Text] [Related]
26. [Effect of B Lymphocyte-Induced Mature Protein-1 Expression in Bone Marrow Mononuclear Cells on Prognosis of Patients with Multiple Myeloma].
Liu GS; Wang JP; Chu ZH; Yu YY; Zhou W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1449-1453. PubMed ID: 29070123
[TBL] [Abstract][Full Text] [Related]
27. The genetic network controlling plasma cell differentiation.
Nutt SL; Taubenheim N; Hasbold J; Corcoran LM; Hodgkin PD
Semin Immunol; 2011 Oct; 23(5):341-9. PubMed ID: 21924923
[TBL] [Abstract][Full Text] [Related]
28. The BTB-ZF transcription factor Zbtb20 is driven by Irf4 to promote plasma cell differentiation and longevity.
Chevrier S; Emslie D; Shi W; Kratina T; Wellard C; Karnowski A; Erikci E; Smyth GK; Chowdhury K; Tarlinton D; Corcoran LM
J Exp Med; 2014 May; 211(5):827-40. PubMed ID: 24711583
[TBL] [Abstract][Full Text] [Related]
29. Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
Butrym A; Łacina P; Rybka J; Chaszczewska-Markowska M; Mazur G; Bogunia-Kubik K
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):151-156. PubMed ID: 28083618
[TBL] [Abstract][Full Text] [Related]
30. Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4/CHOP pathway in multiple myeloma.
Liu H; Xiong C; Liu J; Sun T; Ren Z; Li Y; Geng J; Li X
Biomed Pharmacother; 2020 May; 125():110005. PubMed ID: 32070879
[TBL] [Abstract][Full Text] [Related]
31. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
Ikeda S; Tagawa H
Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
[TBL] [Abstract][Full Text] [Related]
32. BLIMP-1 is insufficient to induce antibody secretion in the absence of IRF4 in DT40 cells.
Budzyńska PM; Kyläniemi MK; Lassila O; Nera KP; Alinikula J
Scand J Immunol; 2018 Mar; 87(3):. PubMed ID: 29430664
[TBL] [Abstract][Full Text] [Related]
33. Unfolded protein response inducers tunicamycin and dithiothreitol promote myeloma cell differentiation mediated by XBP-1.
Jiang H; Zou J; Zhang H; Fu W; Zeng T; Huang H; Zhou F; Hou J
Clin Exp Med; 2015 Feb; 15(1):85-96. PubMed ID: 24356728
[TBL] [Abstract][Full Text] [Related]
34. Multiscale Modeling of Germinal Center Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells Differentiation as Regulated by Antigen Affinity-Based Tfh Cell Help.
Merino Tejero E; Lashgari D; García-Valiente R; Gao X; Crauste F; Robert PA; Meyer-Hermann M; Martínez MR; van Ham SM; Guikema JEJ; Hoefsloot H; van Kampen AHC
Front Immunol; 2020; 11():620716. PubMed ID: 33613551
[TBL] [Abstract][Full Text] [Related]
35. A CRISPR/Cas9-mediated screen identifies determinants of early plasma cell differentiation.
Xiong E; Popp O; Salomon C; Mertins P; Kocks C; Rajewsky K; Chu VT
Front Immunol; 2022; 13():1083119. PubMed ID: 36685499
[TBL] [Abstract][Full Text] [Related]
36. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization.
Jourdan M; Caraux A; De Vos J; Fiol G; Larroque M; Cognot C; Bret C; Duperray C; Hose D; Klein B
Blood; 2009 Dec; 114(25):5173-81. PubMed ID: 19846886
[TBL] [Abstract][Full Text] [Related]
37. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.
Wilkinson ST; Vanpatten KA; Fernandez DR; Brunhoeber P; Garsha KE; Glinsmann-Gibson BJ; Grogan TM; Teruya-Feldstein J; Rimsza LM
Blood; 2012 Feb; 119(6):1459-67. PubMed ID: 22167754
[TBL] [Abstract][Full Text] [Related]
38. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
Gambella M; Rocci A; Passera R; Gay F; Omedè P; Crippa C; Corradini P; Romano A; Rossi D; Ladetto M; Boccadoro M; Palumbo A
Haematologica; 2014 Feb; 99(2):e14-6. PubMed ID: 24497562
[No Abstract] [Full Text] [Related]
39. Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines.
Jiang H; Gao W; Sze DM; Xiong H; Hou J
Int J Hematol; 2007 Dec; 86(5):429-37. PubMed ID: 18192112
[TBL] [Abstract][Full Text] [Related]
40. A role for Blimp1 in the transcriptional network controlling natural killer cell maturation.
Kallies A; Carotta S; Huntington ND; Bernard NJ; Tarlinton DM; Smyth MJ; Nutt SL
Blood; 2011 Feb; 117(6):1869-79. PubMed ID: 21131593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
